Stock Briefing vs Stock Backtest
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
Stock Briefing
Stay informed about your stock portfolio with an AI-powered feed that summarizes market news and sentiment. Listen to audio insights on the go to easily keep up with your investments.
- AI-summarized market news
- Stock sentiment analysis
- Audio insights on the go
- Personalized stock feed
- Intuitive user interface
Read full descriptionHide full description
Imagine a social media feed, but for your stock portfolio. Stock Briefing lets you follow the news and sentiment of the stocks you care about, all in one clean and intuitive app. Our advanced AI summarizes lengthy articles and analyzes the market's reaction, saving you time and keeping you informed. You can also listen to these insights on the go, making it easier than ever to stay ahead. Download Stock Briefing today and Keep up with your stocks effortlessly!
Stock Backtest
Read full descriptionHide full description
$500 a month in TQQQ for 10 years, starting with $500: on past prices from January 2016 to December 2025, with $60,500 paid in, this app's backtest ends at $438K. That is a past result. The same screen shows how far it fell on the way. BacktestLab runs that kind of question on past prices. Put monthly investing next to a single lump sum, or one portfolio next to another, and read them side by side. ■ Whole shares only Many calculators assume fractional shares. This one does not. It buys only the whole shares that the day's price allowed and carries the leftover cash forward. ■ Dividends, reinvested or kept Dividends arrive as cash on the payment date. Reinvest them to buy shares again at that day's price, or keep them as cash and see them counted separately from the final value. ■ Risk next to the return Maximum drawdown, the drawdown chart and named crisis windows sit in the result next to the final value. ■ Build a portfolio Up to ten weighted assets. Choose a rebalancing interval and the original weights are restored on that schedule. ■ Compare Two portfolios over the same period, under the same conditions, side by side. ■ The next 10 years, as an assumption Continue a result with an annual return you enter yourself. It is drawn as an assumption, not as a measurement. ――― This app is a calculator based on past data. It is not investment advice, and past results do not indicate future returns. Taxes and trading fees are not included. No account is created. Calculations run on your device, and your portfolios and saved runs stay there. Available in English and Korean.
Screenshots
Verdict
The clearest difference is in-app purchases: Stock Backtest at none against Stock Briefing's 3. Stock Backtest also leads on iOS requirement (15.0 vs 17.0). On price, ads and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Stock Briefing sells 3 in-app purchases, starting at $1.99 per 7 days. Stock Backtest asks for nothing beyond the download.
| Parameter | Stock Briefing | Stock Backtest |
|---|---|---|
| Price | Free | Free |
| Rating | 4.3 (7 ratings) — better | — |
| Positive reviews | 50.0% of reviews | — |
| Number of ratings | 7 — better | — |
| Update frequency | Every 6 days | — |
| Ads | Yes | Yes |
| In-app purchases | Yes | No — better |
| Monetization | Free with in-app purchases | — |
| Devices | iPhone, iPad | iPhone, iPad, iPod — better |
| Requires iOS | 17.0 | 15.0 — better |
| Further details — not scored | ||
| Size | 78 MB | 25 MB |
| Age rating | 4+ | 4+ |
| Developer | Goodtech LLC | Younghwi Kim |
In-app purchases
Stock Briefing
- StockBriefing Plus Weekly$1.997 Days
- StockBriefing Plus Monthly3 Days trial$3.991 Month
- StockBriefing Plus Yearly$29.991 Year
Stock Backtest
No in-app purchases
Questions
Is Stock Briefing free?
Is Stock Backtest free?
Do Stock Briefing or Stock Backtest have ads?
Other comparisons















